Allergy Therapeutics plc provided revenue guidance for the year ended 30 June 2020. The Group now expects earnings for the full year 2020 to be ahead of market expectations as announced on 24 June 2020. Net revenue is expected to be £78.2 million (2019: £73.7 million) representing 6% annual growth (7% growth on a constant currency basis) reflective of a very robust performance in challenging circumstances. Operating efficiencies and timing of the research and development spend have led to strong overall performance with the Group likely to report a significant, positive net income for the year.